tiprankstipranks
ANEST IWATA Corp. (JP:6381)
:6381
Japanese Market

ANEST IWATA Corp. (6381) AI Stock Analysis

Compare
0 Followers

Top Page

JP:6381

ANEST IWATA Corp.

(6381)

Select Model
Select Model
Select Model
Outperform 75 (OpenAI - 5.2)
Rating:75Outperform
Price Target:
¥1,890.00
▲(15.67% Upside)
Action:ReiteratedDate:10/29/25
ANEST IWATA Corp. demonstrates strong financial performance with solid revenue growth and profitability, supported by a robust balance sheet. While technical indicators suggest some short-term weakness, the stock's valuation remains attractive with a reasonable P/E ratio and a good dividend yield. The absence of recent earnings call data and corporate events does not impact the overall assessment.
Positive Factors
Strong balance sheet / low leverage
Ultra-low leverage and a high equity ratio materially reduce financing risk and increase strategic optionality. Over the next 2–6 months this structural strength supports capital spending, dividend consistency, potential share buybacks or M&A without materially increasing financial stress in downturns.
Negative Factors
Declining EPS trend
A meaningful negative EPS growth rate signals pressure on per‑share earnings that can weigh on long‑term return potential. Over several quarters this can limit balance sheet accruals, constrain payout increases, and indicate margin or mix headwinds that need strategic remediation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet / low leverage
Ultra-low leverage and a high equity ratio materially reduce financing risk and increase strategic optionality. Over the next 2–6 months this structural strength supports capital spending, dividend consistency, potential share buybacks or M&A without materially increasing financial stress in downturns.
Read all positive factors

ANEST IWATA Corp. (6381) vs. iShares MSCI Japan ETF (EWJ)

ANEST IWATA Corp. Business Overview & Revenue Model

Company Description
ANEST IWATA Corporation engages in the air energy and coating businesses in Japan and internationally. The company offers air compressors and nitrogen gas generators for various applications, such as factories, food production, hospitals, electric...
How the Company Makes Money
ANEST IWATA makes money primarily by selling manufactured industrial products and related systems to customers in manufacturing and other industrial sectors. Key revenue streams include: (1) Coating/painting-related equipment sales—revenue generat...

ANEST IWATA Corp. Financial Statement Overview

Summary
ANEST IWATA Corp. exhibits solid financial health with strong revenue growth, profitability, and cash flow generation. The company is well-positioned with a strong balance sheet characterized by low leverage and a high equity ratio, reducing financial risk. Continued focus on efficient operations and cash flow management will further enhance its financial strength.
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
78
Positive
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue54.02B54.41B53.42B48.52B42.34B35.59B
Gross Profit25.43B26.08B24.48B21.34B18.23B14.93B
EBITDA8.31B8.39B8.43B7.91B6.54B5.08B
Net Income4.12B4.28B4.93B4.38B3.54B2.62B
Balance Sheet
Total Assets67.14B69.96B66.14B60.14B55.82B49.46B
Cash, Cash Equivalents and Short-Term Investments18.84B21.34B16.93B14.51B14.32B13.20B
Total Debt2.78B2.87B3.07B2.67B2.42B2.47B
Total Liabilities15.13B16.40B16.07B14.88B15.61B13.32B
Stockholders Equity45.95B46.85B44.16B40.03B35.62B32.24B
Cash Flow
Free Cash Flow0.007.08B4.95B2.48B3.02B4.09B
Operating Cash Flow0.009.75B6.77B4.33B3.89B4.60B
Investing Cash Flow0.00-3.25B-1.26B-3.32B-1.08B-1.07B
Financing Cash Flow0.00-3.93B-3.58B-2.36B-2.10B-1.96B

ANEST IWATA Corp. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1634.00
Price Trends
50DMA
1697.80
Negative
100DMA
1634.57
Negative
200DMA
1563.55
Positive
Market Momentum
MACD
-22.36
Positive
RSI
40.11
Neutral
STOCH
40.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6381, the sentiment is Negative. The current price of 1634 is below the 20-day moving average (MA) of 1669.30, below the 50-day MA of 1697.80, and above the 200-day MA of 1563.55, indicating a neutral trend. The MACD of -22.36 indicates Positive momentum. The RSI at 40.11 is Neutral, neither overbought nor oversold. The STOCH value of 40.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6381.

ANEST IWATA Corp. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥68.84B9.502.63%-6.00%-13.74%
76
Outperform
¥53.40B10.642.79%2.85%3.17%
75
Outperform
¥64.03B13.243.95%-1.67%-4.39%
72
Outperform
¥41.31B12.913.95%1.72%101.76%
70
Outperform
¥134.62B4.158.17%2.04%1.48%58.59%
70
Outperform
¥67.96B4.093.09%6.35%-34.20%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:6381
ANEST IWATA Corp.
1,609.00
453.50
39.25%
JP:6376
Nikkiso Co., Ltd.
2,205.00
916.01
71.06%
JP:6237
Iwaki Co. Ltd.
2,438.00
225.10
10.17%
JP:6333
Teikoku Electric Manufacturing Co., Ltd.
2,849.00
17.42
0.62%
JP:6363
Torishima Pump Mfg.Co., Ltd.
2,589.00
435.03
20.20%
JP:6517
Denyo Co., Ltd.
3,465.00
964.48
38.57%

ANEST IWATA Corp. Corporate Events

ANEST IWATA Revamps Board Lineup With New Outside Director, Maintains Leadership Stability
Mar 18, 2026
ANEST IWATA Corporation has announced a slate of director candidates, primarily consisting of reappointments of its existing leadership team, including President and CEO Eisuke Miyoshi, for approval at its 80th Annual General Meeting of Shareholde...
ANEST IWATA Holds FY2025 Outlook Steady Despite Profit Decline in Q3
Feb 10, 2026
ANEST IWATA reported consolidated net sales of ¥39.49 billion for the third quarter of FY2025, down 1.3% year on year, with operating profit falling 18.1% to ¥3.80 billion as lower sales and higher selling and administrative expenses wei...
ANEST IWATA Posts Lower Q3 Profit but Boosts Dividend as Full-Year Outlook Held
Feb 10, 2026
ANEST IWATA reported FY2025 third-quarter consolidated net sales of ¥39.5 billion, down 1.3% year on year, with operating profit falling 18.1% to ¥3.8 billion and profit attributable to owners of parent slipping 5.6% to ¥3.4 billion...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 29, 2025